Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Early allergy pill may stop sneezing before it starts

NCT ID NCT05692154

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested whether taking the allergy drug fexofenadine for two days before ragweed season can reduce symptoms like sneezing and runny nose. 95 adults with ragweed allergies were randomly given either fexofenadine or a placebo. Researchers measured nasal symptoms over six hours after a pollen challenge to see if early treatment made a difference.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Fexofenadine (an antihistamine drug)
What this could lead to
If it works, this could show that starting allergy medicine a few days before pollen season helps prevent or reduce symptoms.
What could go wrong
This is a small, completed proof-of-concept study, not a large trial. The results may not apply to everyone, and fexofenadine can cause mild side effects like headache or drowsiness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

95 people

The number who actually took part.

Started

Jan 2023

Finished

Mar 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants are eligible to be included in the study only if all of the following criteria apply: * Participant is willing to provide written informed consent. * Adult participants (18 to 80 years old) suffering from seasonal allergic rhinitis (SAR) provoked by Ragweed pollen. * Participants having a total nasal symptom score (TNSS)-3 ≥4 (with 3 nasal symptoms) at first pollen challenge at Visit 2. * Having a 2-year history of SAR with Positive skin prick test to Ragweed allergen at screening (with a wheal diameter at least 3 mm larger than that produced by the negative control). Exclusion Criteria: * History of anaphylaxis to Ragweed pollen History of asthma or exacerbations in the past 12 months requiring regular inhaled corticosteroids for greater than 4 weeks per year, any oral corticosteroid usage, any emergency department visit for asthma or any asthma-related hospitalization. Mild asthmatics treated only with pro re nata short-acting β2agonists, less than 2 doses per week can be enrolled. * History of chronic sinusitis, defined as a sinus symptoms lasting greater than 12 weeks that includes 2 or more major factors or 1 major factor and 2 minor factors. Major factors are defined as facial pain or pressure, nasal obstruction or blockage, nasal discharge or purulence or discolored postnasal discharge, purulence in nasal cavity, or impaired or loss of smell. Minor factors are defined as headache, fever, halitosis, fatigue, dental pain, cough, and ear pain, pressure, or fullness. * History of systemic disease affecting the immune system such as autoimmune diseases, immune complex disease, or immunodeficiency, where, in the opinion of the study physician, participation in the trial would pose a risk or significant effect on the immune system. * Presence or history of drug hypersensitivity to fexofenadine and/or its excipients. * Participants unable to stop the following forbidden treatments/nutriments prior to pollen challenge: * Antihistamines: within 3 days for first-generation antihistamines, within 2 days for second-generation antihistamines. * Intranasal or inhaled corticosteroids: 7 days. * Ocular, intranasal, or inhaled sodium cromoglycate: 14 days. * High doses of systemic corticosteroids: 30 days. * Leukotriene antagonists: 30 days. * Intranasal or systemic decongestants: 3 days. * Tricyclic antidepressants: 7 days. * Any citrus fruits (grapefruit, orange, etc.) or their juices, as well as all fruit juices: 5 days. * Aluminum-and-magnesium containing antacids: 7 days. * Omalizumab/dupilumab: within 6 months * Any contraindications to fexofenadine, according to the labeling. * The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Seasonal allergic rhinitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Investigational Site Number : 1240001

    Kingston, Ontario, K7L 2V7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.